ArticleEuropean journal of pediatrics2025
How familial Mediterranean fever affects the characteristics of immunoglobulin a vasculitis in pediatric patients at the time of diagnosis?
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factors predicting the severity of gastrointestinal involvement in children with IgA vasculitis? A Turkish multicenter cohort study.European journal of pediatrics · 2026Article
- Pediatric Immunoglobulin A Vasculitis: Impact of Mediterranean Fever Gene Variants on Clinical Course and Inflammatory Markers.Turkish archives of pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean fever (FMF) is the most common autoinflammatory disease of childhood and is frequently associated with systemic inflammatory diseases such as vasculitis. The aim of this study is to evaluate the impact of FMF on clinical and laboratory findings and disease activity of immunoglobulin A vasculitis (IgAV) at presentation. Patients with IgAV who were followed up for more than 3 months were included in the study. Patients were divided into two subgroups regarding presence of FMF. Demographic characteristics, clinical findings in the first 3 months, laboratory findings at the time of diagnosis, vasculitis activity scores (PVAS), and treatments administered were recorded. A total of 662 patients with IgAV were included in the study. FMF was diagnosed in 49 (7.4%) patients with IgAV. Patients with FMF had more gastrointestinal tract and renal involvement, higher PVAS score, higher C-reactive protein levels, and higher need for steroids, cyclophosphamide, and intravenous immunoglobulin (p = 0.01, p = 0.03, p < 0.001, p < 0.001, p = 0.04, p < 0.001, p = 0.01, respectively). When patients were analyzed according to MEFV mutations, the effect of FMF on vasculitis was more prominent especially in patients carrying homozygous and compound heterozygous mutations in exon 10.
conclusionFMF may lead to more severe clinical and laboratory findings and disease activity at the time of IgAV diagnosis. The clinician should be aware that the course of IgAV may be affected by the presence of FMF.
trial registrationE2-24-6125, 21.01.2024, retrospectively registered. WHAT IS KNOWN: • In patients with familial Mediterranean fever (FMF), some vasculitides are more common and may affect the course of vasculitis. WHAT IS NEW: • At the time of immunoglobulin A vasculitis diagnosis, patients with FMF may have more system involvement, higher vasculitis activation scores, and acute phase reactants and require more intensive treatment than those without FMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.